These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 26108695)

  • 21. Effect of noncompetitive proteasome inhibition on bortezomib resistance.
    Li X; Wood TE; Sprangers R; Jansen G; Franke NE; Mao X; Wang X; Zhang Y; Verbrugge SE; Adomat H; Li ZH; Trudel S; Chen C; Religa TL; Jamal N; Messner H; Cloos J; Rose DR; Navon A; Guns E; Batey RA; Kay LE; Schimmer AD
    J Natl Cancer Inst; 2010 Jul; 102(14):1069-82. PubMed ID: 20505154
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Endoplasmic reticulum stress and autophagy participate in apoptosis induced by bortezomib in cervical cancer cells.
    Zhang Y; Bai C; Lu D; Wu X; Gao L; Zhang W
    Biotechnol Lett; 2016 Feb; 38(2):357-65. PubMed ID: 26423802
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Therapeutic enhancement of ER stress by insulin-like growth factor I sensitizes myeloma cells to proteasomal inhibitors.
    Tagoug I; Jordheim LP; Herveau S; Matera EL; Huber AL; Chettab K; Manié S; Dumontet C
    Clin Cancer Res; 2013 Jul; 19(13):3556-66. PubMed ID: 23674497
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Bortezomib and IL-12 produce synergetic anti-multiple myeloma effects with reduced toxicity to natural killer cells.
    Wang X; Feng X; Wang J; Shao N; Ji C; Ma D; Henter JI; Fadeel B; Zheng C
    Anticancer Drugs; 2014 Mar; 25(3):282-8. PubMed ID: 24300915
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Anti-β₂-microglobulin monoclonal antibodies overcome bortezomib resistance in multiple myeloma by inhibiting autophagy.
    Zhang M; He J; Liu Z; Lu Y; Zheng Y; Li H; Xu J; Liu H; Qian J; Orlowski RZ; Kwak LW; Yi Q; Yang J
    Oncotarget; 2015 Apr; 6(11):8567-78. PubMed ID: 25895124
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
    Mishima Y; Santo L; Eda H; Cirstea D; Nemani N; Yee AJ; O'Donnell E; Selig MK; Quayle SN; Arastu-Kapur S; Kirk C; Boise LH; Jones SS; Raje N
    Br J Haematol; 2015 May; 169(3):423-34. PubMed ID: 25709080
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Stew in its Own Juice: Protein Homeostasis Machinery Inhibition Reduces Cell Viability in Multiple Myeloma Cell Lines.
    de Oliveira MB; Sanson LFG; Eugenio AIP; Barbosa-Dantas RSS; Colleoni GWB
    Curr Mol Med; 2019; 19(2):112-119. PubMed ID: 30834832
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lycorine Downregulates HMGB1 to Inhibit Autophagy and Enhances Bortezomib Activity in Multiple Myeloma.
    Roy M; Liang L; Xiao X; Peng Y; Luo Y; Zhou W; Zhang J; Qiu L; Zhang S; Liu F; Ye M; Zhou W; Liu J
    Theranostics; 2016; 6(12):2209-2224. PubMed ID: 27924158
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Kuanoniamine C stimulates bortezomib-induced cell death via suppression of glucose-regulated protein 78 in osteosarcoma.
    Machihara K; Namba T
    Biochem Biophys Res Commun; 2020 Jun; 527(1):289-296. PubMed ID: 32446382
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting bortezomib-induced aggresome formation using vinorelbine enhances the cytotoxic effect along with ER stress loading in breast cancer cell lines.
    Miyahara K; Kazama H; Kokuba H; Komatsu S; Hirota A; Takemura J; Hirasawa K; Moriya S; Abe A; Hiramoto M; Ishikawa T; Miyazawa K
    Int J Oncol; 2016 Nov; 49(5):1848-1858. PubMed ID: 27601063
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Blocking of Transient Receptor Potential Vanilloid 1 (TRPV1) promotes terminal mitophagy in multiple myeloma, disturbing calcium homeostasis and targeting ubiquitin pathway and bortezomib-induced unfolded protein response.
    Beider K; Rosenberg E; Dimenshtein-Voevoda V; Sirovsky Y; Vladimirsky J; Magen H; Ostrovsky O; Shimoni A; Bromberg Z; Weiss L; Peled A; Nagler A
    J Hematol Oncol; 2020 Nov; 13(1):158. PubMed ID: 33239060
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Hydroxychloroquine potentiates carfilzomib toxicity towards myeloma cells.
    Baranowska K; Misund K; Starheim KK; Holien T; Johansson I; Darvekar S; Buene G; Waage A; Bjørkøy G; Sundan A
    Oncotarget; 2016 Oct; 7(43):70845-70856. PubMed ID: 27683126
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Circadian Clock REV-ERBs Agonist SR9009 Induces Synergistic Antitumor Activity in Multiple Myeloma by Suppressing Glucose-Regulated Protein 78-Dependent Autophagy and Lipogenesis.
    Wang R; Liu SL; Guo QQ; Shi XH; Ma MM
    World J Oncol; 2023 Dec; 14(6):464-475. PubMed ID: 38022411
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Metformin and chidamide synergistically suppress multiple myeloma progression and enhance lenalidomide/bortezomib sensitivity.
    Mao J; Chen R; Xue L; Zhu Y; Zhao L; Wang J
    Environ Toxicol; 2024 Apr; 39(4):2452-2465. PubMed ID: 38251764
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Metformin triggers apoptosis in PEL cells and alters bortezomib-induced Unfolded Protein Response increasing its cytotoxicity and inhibiting KSHV lytic cycle activation.
    Granato M; Gilardini Montani MS; Romeo MA; Santarelli R; Gonnella R; D'Orazi G; Faggioni A; Cirone M
    Cell Signal; 2017 Dec; 40():239-247. PubMed ID: 28964970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ATF4 destabilizes RET through nonclassical GRP78 inhibition to enhance chemosensitivity to bortezomib in human osteosarcoma.
    Luo J; Xia Y; Yin Y; Luo J; Liu M; Zhang H; Zhang C; Zhao Y; Yang L; Kong L
    Theranostics; 2019; 9(21):6334-6353. PubMed ID: 31534554
    [No Abstract]   [Full Text] [Related]  

  • 37. Bortezomid enhances the efficacy of lidamycin against human multiple myeloma cells.
    Zhen YZ; Lin YJ; Liu XJ; Shang BY; Zhen YS
    Anticancer Drugs; 2013 Jul; 24(6):609-16. PubMed ID: 23698252
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Blockade of HSP70 by VER-155008 synergistically enhances bortezomib-induced cytotoxicity in multiple myeloma.
    Huang L; Wang Y; Bai J; Yang Y; Wang F; Feng Y; Zhang R; Li F; Zhang P; Lv N; Lei L; Hu J; He A
    Cell Stress Chaperones; 2020 Mar; 25(2):357-367. PubMed ID: 32026316
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Extensive immunoglobulin production sensitizes myeloma cells for proteasome inhibition.
    Meister S; Schubert U; Neubert K; Herrmann K; Burger R; Gramatzki M; Hahn S; Schreiber S; Wilhelm S; Herrmann M; Jäck HM; Voll RE
    Cancer Res; 2007 Feb; 67(4):1783-92. PubMed ID: 17308121
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Dyclonine enhances the cytotoxic effect of proteasome inhibitor bortezomib in multiple myeloma cells.
    Ju D; Xie Y
    Mol Med Rep; 2014 Nov; 10(5):2609-12. PubMed ID: 25174315
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.